Intravenous hyperalimentation as an adjunct to cancer chemotherapy.
A 36 per cent response rate was obtained in fifty-eight nutritionally depleted patients with cancer who would otherwise have been denied adequate antitumor therapy because of the fear of complications from malnutrition and inanition. A positive correlation between the nutritional status of the patient and the chemotherapeutic tumor response was identified. Intravenous hyperalimentation can be a valuable adjunct to cancer chemotherapy by improving the nutritional status, increasing the total deliverable dose of anticancer agent per unit of time, and reducing the incidence and severity of the toxic gastrointestinal side effects without adversely stimulating malignant cell growth or producing septic complications.
D000230:Adenocarcinoma / Q000188:drug therapy / Q000628:therapy; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001835:Body Weight; D002100:Cachexia / Q000209:etiology / Q000517:prevention & control*; D005069:Evaluation Studies as Topic; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy / Q000628:therapy*; D009584:Nitrogen / Q000378:metabolism; D010288:Parenteral Nutrition / Q000379:methods*
D000970:Antineoplastic Agents; D009584:Nitrogen; D005472:Fluorouracil